Adebrelimab plus chemoradiation before surgery for thymic carcinoma
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether combining the immunotherapy drug adebrelimab with chemoradiation before surgery can help shrink locally advanced thymic carcinoma and improve outcomes. It is for people who have not yet received treatment for their thymic carcinoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with thymic carcinoma, and the tumor is locally advanced but can potentially be removed with surgery.
- You haven't had any treatment for thymic carcinoma before (including chemo, radiation, or targeted therapy).
- You are in good enough health for a clinical trial (ECOG performance status 0-1).
- Your organs (kidneys, liver, bone marrow) are functioning well enough to handle the study drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether additional chemotherapy after surgery can help prevent thymic cancer from coming back. It is for people who have had their thymus tumor completely removed and are in good health.
This trial tests a new treatment given before surgery for people with advanced thymic carcinoma. It aims to shrink the tumor and make surgery more effective.
This study tests a combination of two drugs (tislelizumab and anlotinib) as a second treatment option for people with thymoma or thymic carcinoma whose cancer has worsened after first-line therapy. It aims to see if this combination can control the tumor and improve outcomes.
This trial tests giving radiation therapy before surgery for a type of thymus gland tumor (thymoma) that has grown into nearby tissues but has not been treated yet. The goal is to see if this approach can make the tumor removable and improve outcomes.
This trial tests adding a drug called adebrelimab to standard chemotherapy and possibly radiation, given before surgery for breast cancer that is HER2-negative and locally advanced. The goal is to see if this combination helps shrink tumors more effectively, potentially allowing for breast-conserving surgery.
This trial tests adding the immunotherapy drug Adebrelimab to standard chemotherapy before surgery for people with stage II or III non-small cell lung cancer (the most common type) that can be removed. The goal is to see if this combination shrinks tumors more effectively and improves outcomes.
Hear when a new Thymic Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.